Phase I
Q32 Bio rakes in $60 million Series B as they dose their first patient in IL-7R antibody trial.
On October 14th, Amolyt Pharma announced the first dosing in its Phase I trial of AZP-3601 in healthy subjects, a momentous occasion capping off years of hard work in pre-clinical development. The drug aims to walk the biological tightrope in the management of hypoparathyroidism, a rare disease causing muscular pain and cognitive challenges.
Recent Greenphire data shows new participant enrollment up 85% since slump in April.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.
It was another busy week for clinical trial updates and news. Here’s a look.
Finding and developing an effective treatment for nonalcoholic steatohepatitis has, so far, been met with as much futility and frustration as developing a treatment for Alzheimer’s disease. Sagimet Biosciences Chief Executive Officer George Kemble believes his company is on the right path, though.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.
Intellia has received approval to launch their Phase I trial of NTLA-2001 in hereditary ATTR.
It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020.
PRESS RELEASES